Effectiveness, persistence and safety of E/C/F/TAF, F/TAF+3rd agent or R/F/TAF in treatment-experienced HIV-1 infected patients: 12-month results from the German TAFNES cohort study

被引：0
|
作者：
Hillenbrand, H. [1 ]
Knechten, H. [2 ]
Kuemmerle, T. [3 ]
Scholten, S. [4 ]
Schuebel, N. [5 ]
Haubrich, R. [6 ]
Heinzkill, M. [7 ]
Goerner, K. [7 ]
Stellbrink, H. [8 ]
机构：
[1] MVZ Praxis City Ost, Clin Care, Berlin, Germany
[2] Praxis Dr Knechten, Clin Care, Aachen, Germany
[3] Praxis Ebertplatz, Clin Care, Cologne, Germany
[4] Praxis Hohenstaufenring, Cologne, Germany
[5] Klinikum Osnabruck, Clin Care, Osnabruck, Germany
[6] Gilead Sci, Clin Sci, Foster City, CA USA
[7] Gilead Sci, Clin Sci, Munich, Germany
[8] ICH Study Ctr, Clin Care, Hamburg, Germany
来源：
JOURNAL OF THE INTERNATIONAL AIDS SOCIETY | 2018年 / 21卷
关键词：
D O I：
暂无
中图分类号：
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号：
100102 ;
摘要：
P069
引用
收藏
页数：2
相关论文
共 37 条
  • [31] A phase 3b, open-label, pilot study to evaluate switching to elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide (E/C/F/TAF) in virologically-suppressed HIV-1 infected adult subjects harboring NRTI resistance mutations M184V/I +/- TAMs (GS-US-292-1824): week 24 results
    Perez-Valero, I.
    Llibre, J. M.
    Lazzarin, A.
    Di Perri, G.
    Pulido, F.
    Molina, J-M
    Esser, S.
    Margot, N.
    Shao, Y.
    Piontkowsky, D.
    Das, M.
    McNicholl, I.
    Haubrich, R.
    [J]. HIV MEDICINE, 2019, 20 : 170 - 171
  • [32] Efficacy and safety of switching from boosted protease inhibitor plus emtricitabine/tenofovir disoproxil fumarate regimens to the single-tablet regimen of darunavir/cobicistat/emtricitabine/tenofovir alafenamide (D/C/F/TAF) in virologically suppressed, HIV-1-infected adults through 24 weeks: EMERALD study
    Molina, J-M
    Gallant, J.
    Orkin, C.
    Negredo, E.
    Bhatti, L.
    Gathe, J.
    Van Landuyt, E.
    Lathouwers, E.
    Hufkens, V.
    Vanveggel, S.
    Opsomer, M.
    [J]. JOURNAL OF THE INTERNATIONAL AIDS SOCIETY, 2017, 20 : 28 - 28
  • [33] A phase 3b, open-label, pilot study to evaluate switching to elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide (E/C/F/TAF) in virologically-suppressed HIV-1 infected adult subjects harboring the NRTI resistance mutation M184V and/or M184I (GS-US-292-1824)
    Valero, I. Perez
    Llibre, J. M.
    Lazzarin, A.
    Di Perri, G.
    Pulido, F.
    Molina, J. -M.
    Esser, S.
    McNicholl, I.
    Lorgeoux, R. -P.
    Margot, N.
    Shao, Y.
    Piontkowsky, D.
    Das, M.
    Haubrich, R.
    [J]. JOURNAL OF THE INTERNATIONAL AIDS SOCIETY, 2018, 21 : 6 - 7
  • [34] Prevalence of archived HIV-1 DNA resistance-associated mutations (RAMs) and their lack of effect on virologic outcome at week 96 in antiretroviral treatment (ART)-experienced, virologically suppressed patients receiving the once-daily, single-tablet regimen (STR) darunavir/cobicistat/emtricitabine/tenofovir alafenamide (D/C/F/TAF) in the EMERALD phase III trial
    Lathouwers, E.
    Murrow, S.
    Baugh, B.
    Ghys, A.
    Jezorwski, J.
    Mohsine, E. G.
    Opsomer, M.
    De Meyer, S.
    [J]. HIV MEDICINE, 2019, 20 : 97 - 97
  • [35] A phase 3b open-label pilot study to evaluate switching to elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide (E/C/F/TAF) single tablet regimen (STR) in virologically suppressed HIV-1 infected adults harbouring the NRTI resistance mutation M184V and/or M184I (GS-US-292-1824)
    Perez-Valero, I.
    Llibre, J. M.
    Pulido, F.
    Molina, J-M
    Esser, S.
    McNicholl, I.
    Lorgeoux, R-P
    Piontkowsky, D.
    Sathia, L.
    Haubrich, R.
    [J]. HIV MEDICINE, 2018, 19 : S21 - S21
  • [36] Week-48 results of AMBER: phase 3, randomised, double-blind trial in antiretroviral treatment (ART)-naive HIV-1-infected adults to evaluate the efficacy and safety of the once-daily, single-tablet regimen (STR) of darunavir/cobicistat/emtricitabine/tenofovir alafenamide (D/C/F/TAF) versus darunavir/cobicistat (DRV/c) plus emtricitabine/tenofovir disoproxil fumarate (FTC/TDF)
    Gallant, J.
    Orkin, C.
    Molina, J-M
    Negredo, E.
    Antinori, A.
    Mills, A.
    Eron, J.
    Reynes, J.
    van Landuyt, E.
    Hufkens, V.
    Jezorwski, J.
    Opsomer, M.
    [J]. HIV MEDICINE, 2018, 19 : S32 - S32
  • [37] Week 48 results of EMERALD: a Phase 3, randomised, non-inferiority study evaluating the efficacy and safety of switching from boosted-protease inhibitors (bPI) plus emtricitabine (FTC)/tenofovir disoproxil fumarate (TDF) regimens to the once daily (QD), single-tablet regimen (STR) of darunavir/cobicistat/emtricitabine/tenofovir alafenamide (D/C/F/TAF) in virologically suppressed, HIV-1-infected adults
    Orkin, C.
    Molina, J-M
    Gallant, J.
    Negredo, E.
    Gathe, J.
    Eron, J.
    van Landuyt, E.
    Lathouwers, E.
    Hufkens, V.
    Petrovic, R.
    Opsomer, M.
    [J]. HIV MEDICINE, 2018, 19 : S32 - S32
1234